This Pharma Intermediates Stock Rises 137% in 1 Year: Can the CDMO Boom Justify the Price?

This pharma intermediates stock has returned approximately 136.7% over the past year, placing it among the top 31 performers on a screen of 195 NSE small-cap stocks dated 11 September 2026. The rally in this pharma intermediates stock has been built on profit that more than doubled in FY26, a sharp rise in margins and new businesses in battery and semiconductor chemicals.

The company is Acutaas Chemicals Ltd (NSE: ACUTAAS), which was known as Ami Organics until it changed its name on 15 May 2025. The Acutaas Chemicals share closed at Rs 3,451.40 on 10 September 2026, up about 6.5% on the day after a domestic brokerage upgraded it, giving the company a market value of approximately Rs 28,256 crore.

Click Here – Get Free Investment Predictions

How Much Has This Pharma Intermediates Stock Gained?

The pharma intermediates stock rose from a close of Rs 1,458.30 on 10 September 2025 to Rs 3,451.40 on 10 September 2026, a gain of approximately 136.7%. Over the same period, the share traded between a low of Rs 1,302 in late September 2025 and a record Rs 3,740 in July 2026.

Period	Return (%)
1 Month	Approximately 5.2%
6 Months	Approximately 54.9%
1 Year	Approximately 136.7%
3 Years	Approximately 419.7%
Versus IPO price (Sep 2021, split-adjusted Rs 305)	Approximately 1,031.6%

The company split each Rs 10 share into two shares of Rs 5 with a record date of 25 April 2025. That split falls before the 1-year window, and all older prices above are adjusted for it, so the returns reflect real price movement and not a change in share count.

The pharma intermediates stock listed in September 2021 at an IPO price of Rs 610, which works out to Rs 305 after the split. It hit a record Rs 3,740 in July 2026 and is about 8% below that level now. On 11 September 2026, the pharma intermediates stock was trading around Rs 3,431 in the afternoon.

Why Did This Pharma Intermediates Stock Rise So Much?

This pharma intermediates stock rose because earnings grew much faster than sales, margins widened by more than 14 percentage points in a year, and investors began to value new lines such as battery chemicals and contract manufacturing. Each quarterly result in the past year beat the previous year by a wide margin.

1. Profit Growth Far Ahead of Sales Growth

FY26 revenue from operations rose 33% to approximately Rs 1,339 crore, while profit after tax rose around 122% to Rs 356 crore. EBITDA more than doubled to about Rs 480 crore. The gap came from a richer product mix and fixed costs being spread over a larger sales base.

For a pharma intermediates stock, that kind of margin jump is unusual. Operating EBITDA margin rose to about 35.9% in FY26 from roughly 23% in FY25, and touched 42.4% in the March 2026 quarter.

2. Quarter After Quarter of Strong Results

The run began in October 2025, when the September quarter profit rose about 93.5% and the pharma intermediates stock hit a then-record near Rs 1,650. The December quarter followed with profit up about 140% and EBITDA margin of 38.3%, and management raised FY26 growth guidance to 30% from 25%.

The March 2026 quarter was the strongest, with revenue up about 40% and profit up about 114% to around Rs 134 crore. That result pushed the pharma intermediates stock to fresh highs through May and June 2026.

3. Advanced Intermediates and CDMO Work

The core business behind this pharma intermediates stock makes advanced intermediates used by drug companies to produce active ingredients. This segment formed about 88% of FY26 revenue, and in the June 2026 quarter it grew about 76.5% year on year to around Rs 293 crore.

A growing share of this comes from contract development and manufacturing (CDMO) work for global drugmakers. Management targets CDMO revenue above Rs 1,000 crore by FY28, and says it adds 30 to 40 new molecules to its pipeline each year. This is a large part of why the market now values the pharma intermediates stock at a premium.

4. Battery and Semiconductor Chemicals

The company behind this pharma intermediates stock has started commercial supply of battery electrolyte additives, which it describes as seeing strong demand under long-term customer contracts. It is also building a plant in South Korea through a joint venture called Indikem to make ultra-pure materials used in chip manufacturing.

The Korea plant is expected to be completed around the end of the March 2027 quarter, with revenue from FY28. These newer lines gave the company a second growth story that pushed it to a record Rs 2,727 in early May 2026.

5. Rising Foreign Ownership and a Recent Upgrade

Foreign portfolio investors raised their holding in the pharma intermediates stock from about 16.9% in June 2025 to about 21.6% in June 2026. On 10 September 2026, a domestic brokerage upgraded the pharma intermediates stock to buy, and the share jumped about 6.5% that day on volume roughly five times its recent daily average.

Check the Univest Screener for Live Fundamentals of High-Return Stocks

Pharma Intermediates Stock Financials: Quarterly Trend

The table below shows consolidated quarterly figures in Rs crore, with revenue including other income. The March 2026 quarter was the peak, and the June 2026 quarter was lower on a sequential basis but well above the year-earlier level.

Quarter	Revenue	EBITDA	Net Profit	Net Margin
Jun 2025	223.18	66.84	44.01	21.37%
Sep 2025	316.04	105.16	71.86	23.59%
Dec 2025	397.88	155.35	106.22	27.46%
Mar 2026	443.86	194.62	134.28	30.45%
Jun 2026	331.47	114.87	74.99	22.53%

In the June 2026 quarter, revenue from operations rose about 59.1% year on year to approximately Rs 330 crore, and profit rose about 70% to around Rs 75 crore. Operating EBITDA margin was 34.3%, up from about 24.6% a year earlier.

Revenue fell about 24% from the March quarter, however, and the pharma intermediates stock dropped about 6% on the day the numbers came out. Management kept its FY27 guidance of approximately 25% revenue growth with EBITDA margin of 32% to 33%, lower than the 35.9% achieved in FY26.

The balance sheet of this pharma intermediates stock is strong. Debt-to-equity stands at about 0.02, equity rose to approximately Rs 1,711 crore in FY26, and operating cash flow was about Rs 292 crore against capital spending of around Rs 328 crore.

Is This Pharma Intermediates Stock Expensive?

Yes, on current earnings this pharma intermediates stock trades at a large premium. Its trailing PE ratio is approximately 72.95 times, against an industry PE of around 38.02 times.

Metric	Value
Market Cap	Approx Rs 28,256 Cr
PE Ratio (TTM)	72.95
Industry PE	38.02
Price to Book	17.09
ROE	21.54%
Debt to Equity	0.02
Dividend Yield	0.07%

The market is paying for growth that has not yet shown up in the numbers, especially from CDMO, battery and chip chemicals. If those businesses scale as planned, the multiple could come down as earnings rise. If they are delayed, the pharma intermediates stock has little valuation support at these levels.

Who Owns This Pharma Intermediates Stock?

Promoter holding in this pharma intermediates stock has stayed flat at 32.66% for the past five quarters. The main change has been a steady rise in foreign institutional ownership, while domestic institutions trimmed slightly.

Holder	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	32.66%	32.66%	32.66%	32.66%	32.66%
FII	16.94%	16.85%	16.67%	19.48%	21.61%
DII	22.38%	22.59%	21.70%	19.60%	19.56%
Public	28.02%	27.91%	28.97%	28.25%	26.17%

A large sovereign pension fund held about 3.5% as of June 2026, and a multicap mutual fund scheme held a similar stake. The fall in public holding from about 28% to about 26% suggests shares are moving from retail hands to institutions, which often happens as a pharma intermediates stock gains coverage.

Risks for This Pharma Intermediates Stock

The main risks are valuation, lumpy quarterly sales, execution in new businesses and the usual volatility of a small-cap share. Anyone tracking this pharma intermediates stock should weigh these alongside the growth numbers.

1. Rich Valuation

At around 73 times trailing earnings, the stock is priced for strong growth for several years. Any miss on guidance could lead to a sharp fall, as seen when the pharma intermediates stock dropped about 6% after the June 2026 quarter results.

2. Uneven Quarterly Revenue

For a pharma intermediates stock, CDMO orders often come in batches, so revenue can swing sharply between quarters. The drop of about 24% in June quarter revenue from March shows how a single quarter can look weak even within a strong year.

3. Customer and Product Concentration

A meaningful part of sales is linked to intermediates for a small number of large drugs, including the blood thinner apixaban. Patent expiries, customer inventory cuts or pricing pressure from Chinese suppliers could hurt a pharma intermediates stock with this profile.

4. Execution in Battery and Chip Chemicals

The Korea chip materials plant and the battery electrolyte business are new areas. Delays in plant completion, customer approvals or demand could push revenue beyond FY28 and weaken the growth story behind the Acutaas Chemicals share.

5. Small-Cap Liquidity and Volatility

As a small-cap pharma intermediates stock, daily trading value is limited, averaging around Rs 82 crore over the three months to June 2026. The share moved between Rs 1,302 and Rs 3,740 in a year and fell about 17% within weeks in late July 2026, so sharp swings in both directions are likely.

Download the Univest iOS App or Univest Android App to track the Acutaas Chemicals share price live

Acutaas Chemicals Share: Analyst View

Most brokerage coverage on this pharma intermediates stock is positive, but views on price are spread widely because of the high valuation. Analysts mainly point to CDMO growth, margin gains and the new specialty businesses.

A domestic brokerage upgraded the stock to buy from add on 10 September 2026. It expects the CDMO business to grow about 28% a year from FY26 to FY30, and the specialty chemicals segment, including electrolyte additives and chip chemicals, to grow from about Rs 170 crore to Rs 730 crore over the same period. It also sees a recovery in legacy intermediates as the apixaban patent expires in November 2026.

Acutaas Chemicals Share Price Target

The latest verified Acutaas Chemicals share price target is Rs 3,800 from that domestic brokerage, about 10% above the 10 September close of Rs 3,451.40. Earlier, in March 2026, two domestic brokerages had set targets of Rs 2,350 and Rs 2,501, both of which the stock has since passed.

Across a poll of about 10 analysts, the average Acutaas Chemicals share price target is lower than the current price at around Rs 2,973, with estimates ranging from about Rs 1,423 to Rs 4,001. That spread shows how differently analysts view the pharma intermediates stock at this level.

For reference, the Acutaas Chemicals share price record of Rs 3,740 marks the top of the range, and the 52-week low of Rs 1,302 marks the bottom. Any Acutaas Chemicals share price target is an opinion and can change quickly with results.

Other Stocks to Track From the Same Return Screen

Beyond this pharma intermediates stock, a screen of 195 small-cap NSE stocks dated 11 September 2026 also includes related names such as Bliss GVS with a 1-year return of 358.71%, Shilpa Medicare at 125.18% and Garware Hi-Tech Films at 107.98%.

Among the names covered from that screen, MTAR Technologies returned 396.53% over one year. Readers can compare this pharma intermediates stock with the Nifty 50 benchmark and track each of these names on Univest before making any decision.

Conclusion

This pharma intermediates stock has returned approximately 137% over one year, driven by profit that more than doubled in FY26, margins that rose to around 36% and a growing CDMO pipeline. New battery and semiconductor chemical lines add a longer-term angle that the market has started to price in.

Against that, the Acutaas Chemicals share price now trades at about 73 times earnings, quarterly revenue can swing sharply, and small-cap volatility has been high. The next few quarters, especially progress on CDMO molecules and the Korea plant, will decide whether this pharma intermediates stock can grow into its valuation.

Frequently Asked Questions

Which pharma intermediates stock has risen 137% in 1 year?

Ans. Acutaas Chemicals Ltd (NSE: ACUTAAS), formerly Ami Organics, rose approximately 136.7% in one year, from Rs 1,458.30 on 10 September 2025. It closed at Rs 3,451.40 on 10 September 2026.

What is the Acutaas Chemicals share price today?

Ans. The pharma intermediates stock closed at Rs 3,451.40 on 10 September 2026 and traded around Rs 3,431 on 11 September. Its 52-week range is Rs 1,302 to Rs 3,740.

Is Acutaas Chemicals the same company as Ami Organics?

Ans. Yes. Ami Organics Ltd, the pharma intermediates stock, changed its name to Acutaas Chemicals Ltd with effect from 15 May 2025, and the NSE symbol changed to ACUTAAS. The business and management remain the same.

Did Acutaas Chemicals split its shares?

Ans. Yes. Each Rs 10 share was split into two shares of Rs 5 with a record date of 25 April 2025. This happened before the 1-year window, so the 1-year return of about 137% is not affected by the split.

What is the Acutaas Chemicals share price target?

Ans. A domestic brokerage set a Rs 3,800 target on the stock on 10 September 2026 with a buy rating. The average of about 10 analysts is around Rs 2,973, below the current price.

Why did Acutaas Chemicals shares rise?

Ans. FY26 profit rose about 122% to Rs 356 crore on 33% revenue growth, with EBITDA margin rising to about 35.9%. Growth in CDMO work at the pharma intermediates stock, new battery chemicals and a planned chip materials plant in Korea also lifted investor interest.

What were Acutaas Chemicals Q1 FY27 results?

Ans. In the June 2026 quarter, revenue from operations rose about 59.1% year on year to around Rs 330 crore, and profit rose about 70% to around Rs 75 crore. Revenue was about 24% lower than the March quarter.

What are the main risks for Acutaas Chemicals?

Ans. The key risks for this pharma intermediates stock are a PE of about 73 times, uneven quarterly revenue, reliance on a few large drug intermediates, execution risk in new businesses and small-cap volatility. The stock has swung between Rs 1,302 and Rs 3,740 in a year.